1. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study 
Cesare Battaglia, M.D., Ph.D., Fulvia Mancini, M.D., Ph.D., Raffaella Fabbri, B.D., Nicola Persico, M.D., Paolo Busacchi, M.D., Fabio Facchinetti, M.D., Stefano Venturoli, M.D. 
Fertility and Sterility 
Volume 94, Issue 4, Pages (September 2010)
DOI: /j.fertnstert
Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

2. Figure 1
Brachial artery ultrasound and Doppler analyses. Upper panel: 15 seconds after reactive hyperemia, in basal conditions and after treatment, the percentage change in the brachial artery diameter was similar in Yasmin- and in NuvaRing-treated patients with PCOS. At 120 seconds, hyperemia was still present. Its results were similar in both groups. Lower panel: 15 seconds after reactive hyperemia, in basal conditions and after treatment, the percentage change in brachial artery PI was similar in Yasmin- and in NuvaRing-treated patients with PCOS. At 120 seconds, hyperemia was still present. No significant differences were observed between the groups.
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

3. Figure 2
Total cholesterol/LDL (upper panel) and HDL/LDL (lower panel) ratios were unchanged after 6 months of therapy with Yasmin (group I) or with NuvaRing (group II).
Fertility and Sterility  , DOI: ( /j.fertnstert )
Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions